The estimated Net Worth of Bioequities Master Fund Lpm... is at least $59.9 Million dollars as of 19 February 2004. Bioequities Lpm owns over 172,373 units of Rigel Pharmaceuticals stock worth over $56,426,193 and over the last 21 years Bioequities sold RIGL stock worth over $3,447,460.
Bioequities has made over 1 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Bioequities sold 172,373 units of RIGL stock worth $3,447,460 on 19 February 2004.
The largest trade Bioequities's ever made was selling 172,373 units of Rigel Pharmaceuticals stock on 19 February 2004 worth over $3,447,460. On average, Bioequities trades about 172,373 units every 0 days since 2004. As of 19 February 2004 Bioequities still owns at least 4,350,516 units of Rigel Pharmaceuticals stock.
You can see the complete history of Bioequities Lpm stock trades at the bottom of the page.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: